With 0.7 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.19 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.7 whereas the lowest price it dropped to was $2.128. The 52-week range on NCEL shows that it touched its highest point at $33.70 and its lowest point at $1.89 during that stretch. It currently has a 1-year price target of $1600.00. Beta for the stock currently stands at 0.15.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NCEL was down-trending over the past week, with a drop of -10.80%, but this was down by -37.01% over a month. Three-month performance dropped to -88.82% while six-month performance fell -90.18%. The stock gained 17.37% in the past year, while it has lost -89.43% so far this year.
Float and Shares Shorts:
At present, 4.56 million NCEL shares are outstanding with a float of 4.07 million shares on hand for trading. On 2025-12-15, short shares totaled 41855.0, which was 8.0 higher than short shares on 1763078400. In addition to Mr. Ronen Twito CPA as the firm’s CEO & Executive Chairman, Prof. Michel Revel M.D., Ph.D. serves as its Co-Founder, Chief Scientist, Head of the Scientific Advisory Board & Director.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$16 being high and -$16 being low. For NCEL, this leads to a yearly average estimate of -$16.
